# Deduplicated Content: Group 195

## Overview

This group contains **2 related documents** with varying content completeness.

**Most Complete Document:** [HOUSE_OVERSIGHT_026362](../documents/HOUSE_OVERSIGHT_026362.md)

## Documents in This Group

| Bates ID | Pages | Date | Characters | Relationship |
|----------|-------|------|------------|-------------|
| [HOUSE_OVERSIGHT_026362](../documents/HOUSE_OVERSIGHT_026362.md) | 11 | Unknown | 15,341 | Complete (100%) |
| [HOUSE_OVERSIGHT_025888](../documents/HOUSE_OVERSIGHT_025888.md) | 9 | Unknown | 14,588 | Complete (100%) |

## Content Comparison

### Version 1: HOUSE_OVERSIGHT_026362 (Most Complete)

??? info "Document Metadata"
    - **Bates ID:** [HOUSE_OVERSIGHT_026362](../documents/HOUSE_OVERSIGHT_026362.md)
    - **Pages:** 11
    - **Characters:** 15,341
    - **Words:** 2,367
    - **Custodian:** Epstein, Jeffrey

??? abstract "Content Preview"
    From: jeffrey E. [jeevacation@gmail.com] 
    Sent: 7/24/2015 8:47:39 PM 
    To: Sultan Bin Sulayem 
    Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today 
    yes, it requires a shot, its not a pill and so far no long term effects known 
    On Fri, Jul 24, 2015 at 4:37 PM, Sultan Bin Sulayem < 
    Have you heard of this colestrol 
    Jul 24, 2015 @ 3:23 PM 1,169 views 
    _ wrote: 
    The FDA Approves A Potent And Pricey 
    Cholesterol-Lowering Shot 
    Matthew Herper, 
    Forbes Staff 
    I cover science and medicine, and believe this is biology's century. 
    • Follow on Forbes  
    f1970)  
    Full Bio 
    Recent Posts 
    • Popular Posts 
    I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome 
    Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on 
    Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. 
    Loading... 
    Loading... 
    The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who 
    have established heart disease, for people whose risk of a heart attack or stroke is not being adequately 
    controlled by existing drugs called statins. 
    It might be a big step in the battle against heart disease — and the approval is a triumph for Regeneron 
    Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be 
    more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost 
    HOUSE OVERSIGHT 026362 
    down the line. 
    "Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to 
    treat patients who have been extremely difficult to treat with high levels of LDL cholesterol," says Steven 
    Nissen, chairman of cardiology at the Cleveland Clinic. "It's very promising." 
    But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant 
    pharmacy benefits manager."If these 
    
    [...content truncated...]
    


---

### Version 2: HOUSE_OVERSIGHT_025888 (Most Complete)

??? info "Document Metadata"
    - **Bates ID:** [HOUSE_OVERSIGHT_025888](../documents/HOUSE_OVERSIGHT_025888.md)
    - **Pages:** 9
    - **Characters:** 14,588
    - **Words:** 2,250
    - **Custodian:** Epstein, Jeffrey

??? abstract "Content Preview"
    From: Sultan Bin Sulayem 
    Sent: 7/24/2015 8:37:24 PM 
    To: Jeffrey Epstein [jeevacation@gmail.com] 
    Subject: Fwd: FDA Approved a Potent and Pricey Cholesterol lowering drug today 
    Importance: High 
    Have you heard of this colestrol 
    Jul 24, 2015 @ 3:23 PM 1,169 views 
    The FDA Approves A Potent And Pricey 
    Cholesterol-Lowering Shot 
    Matthew Herper, 
    Forbes Staff 
    I cover science and medicine, and believe this is biology's century. 
    • Follow on Forbes  
    (1970) 
    Full Bio 
    Recent Posts 
    Popular Posts 
    I believe this is biology's century. I've covered science and medicine for Forbes from the Human Genome 
    Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on 
    Twitter, circle me onGoogle Plus, or subscribe to my Facebook page. 
    Loading... 
    Loading... 
    The Food and Drug Administration has approved Praluent, a new medicine to lower cholesterol in people who 
    have established heart disease, for people whose risk of a heart attack or stroke is not being adequately 
    controlled by existing drugs called statins. 
    It might be a big step in the battle against heart disease — and the approval is a triumph for Regeneron 
    Pharmaceuticals, the Tarrytown, N.Y.-based biotechnology company that invented it. Praluent is likely to be 
    more widely used, and to cost more, than Wall Steet analysts expected. That also means it could be a big cost 
    down the line. 
    "Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to 
    treat patients who have been extremely difficult to treat with high levels of LDL cholesterol," says Steven 
    HOUSE OVERSIGHT 025888 
    Nissen, chairman of cardiology at the Cleveland Clinic. "It's very promising." 
    But it will also be very expensive, say Troy Brennan, the chief medical officer of CVS Caremark, the giant 
    pharmacy benefits manager."If these drugs are used as broadly as they could be used, they are going to be by far 
    the most expensive drug class," Brennan says.
    
    [...content truncated...]
    

**Compared to most complete version:**
- Missing: 753 characters, 117 words

---

## Additional Information

